A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/jo/volume-2022/3982539/figures/3982539.fig.002a.svgz" name="3982539.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Overall Survival</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/jo/volume-2022/3982539/figures/3982539.fig.002b.svgz" name="3982539.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Disease Specific Survival</td></tr><tr class="fig-image" id="c"><td><object data="https://static.hindawi.com/articles/jo/volume-2022/3982539/figures/3982539.fig.002c.svgz" name="3982539.fig.002c" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(c) </b>Overall Survival</td></tr><tr class="fig-image" id="d"><td><object data="https://static.hindawi.com/articles/jo/volume-2022/3982539/figures/3982539.fig.002d.svgz" name="3982539.fig.002d" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(d) </b>Disease Free Survival</td></tr></table>

<div>Multifaceted prognostic analysis of UBE2S at pan-cancer level. (a) The association of UBE2S with OS and DSS in pan-cancers from TCGA database. (b) Survival maps and survival curves of OS (c) and DFS (d) were delineated to elaborate and validate UBE2S prognostic values using GEPIA2 tool.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective 

Figure 2 | A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective 